Inspire Medical Systems PE Ratio 2017-2026 | INSP
Current and historical p/e ratio for Inspire Medical Systems (INSP) from 2017 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Inspire Medical Systems PE ratio as of June 15, 2026 is 20.94.
| Inspire Medical Systems PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-06-16 | 41.39 | 9.22 | |
| 2026-03-31 | 51.58 | $4.49 | 11.49 |
| 2025-12-31 | 92.23 | $4.98 | 18.52 |
| 2025-09-30 | 74.20 | $1.49 | 49.80 |
| 2025-06-30 | 129.77 | $1.75 | 74.15 |
| 2025-03-31 | 159.28 | $2.19 | 72.73 |
| 2024-12-31 | 185.38 | $1.75 | 105.93 |
| 2024-09-30 | 211.05 | $1.09 | 193.62 |
| 2024-06-30 | 133.83 | $0.20 | 669.15 |
| 2024-03-31 | 214.79 | $-0.53 | 0.00 |
| 2023-12-31 | 203.43 | $-0.72 | 0.00 |
| 2023-09-30 | 198.44 | $-1.09 | 0.00 |
| 2023-06-30 | 324.64 | $-1.40 | 0.00 |
| 2023-03-31 | 234.07 | $-1.52 | 0.00 |
| 2022-12-31 | 251.88 | $-1.60 | 0.00 |
| 2022-09-30 | 177.37 | $-1.82 | 0.00 |
| 2022-06-30 | 182.67 | $-1.60 | 0.00 |
| 2022-03-31 | 256.69 | $-1.55 | 0.00 |
| 2021-12-31 | 230.06 | $-1.54 | 0.00 |
| 2021-09-30 | 232.88 | $-1.71 | 0.00 |
| 2021-06-30 | 193.26 | $-1.72 | 0.00 |
| 2021-03-31 | 206.99 | $-2.12 | 0.00 |
| 2020-12-31 | 188.09 | $-2.19 | 0.00 |
| 2020-09-30 | 129.05 | $-2.33 | 0.00 |
| 2020-06-30 | 87.02 | $-2.28 | 0.00 |
| 2020-03-31 | 60.28 | $-1.72 | 0.00 |
| 2019-12-31 | 74.21 | $-1.40 | 0.00 |
| 2019-09-30 | 61.02 | $3.19 | 19.13 |
| 2019-06-30 | 60.65 | $3.31 | 18.32 |
| 2019-03-31 | 56.78 | $3.20 | 17.74 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $1.555B | $0.912B |
| Inspire Medical Systems Inc. is a medical technology company. It focused on the development and commercialization of solutions for obstructive sleep apnea. The company's proprietary Inspire therapy is a neurostimulation technology which provides treatment for moderate to severe obstructive sleep apnea. Inspire Medical Systems Inc.is based in Minnesota, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $24.733B | 27.19 |
| Tempus AI (TEM) | United States | $7.677B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $4.429B | 38.86 |
| Doximity (DOCS) | United States | $3.888B | 16.84 |
| IRhythm Holdings (IRTC) | United States | $3.724B | 0.00 |
| 10x Genomics (TXG) | United States | $2.973B | 0.00 |
| Privia Health (PRVA) | United States | $2.810B | 131.59 |
| Hinge Health (HNGE) | United States | $2.789B | 0.00 |
| Heartflow (HTFL) | United States | $2.311B | 0.00 |
| Omnicell (OMCL) | United States | $1.564B | 43.00 |
| Enovis (ENOV) | United States | $1.405B | 7.40 |
| Butterfly Network (BFLY) | United States | $1.047B | 0.00 |
| Azenta (AZTA) | United States | $1.023B | 41.13 |
| Clover Health Investments (CLOV) | United States | $1.013B | 0.00 |
| Talkspace (TALK) | United States | $0.864B | 103.40 |
| Schrodinger (SDGR) | United States | $0.839B | 0.00 |
| Phreesia (PHR) | United States | $0.490B | 50.38 |
| Fulgent Genetics (FLGT) | United States | $0.429B | 0.00 |
| Standard BioTools (LAB) | United States | $0.345B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.322B | 0.00 |
| CapsoVision (CV) | United States | $0.311B | 0.00 |
| Senseonics Holdings (SENS) | United States | $0.279B | 0.00 |
| Claritev (CTEV) | United States | $0.269B | 0.00 |
| TruBridge (TBRG) | United States | $0.268B | 8.60 |
| Evolent Health (EVH) | United States | $0.260B | 0.00 |
| Carlsmed (CARL) | United States | $0.239B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.196B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.189B | 0.00 |
| CareCloud (CCLD) | United States | $0.115B | 8.18 |
| Nyxoah SA (NYXH) | Belgium | $0.111B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.102B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.101B | 0.00 |
| American Well (AMWL) | United States | $0.086B | 0.00 |
| Outset Medical (OM) | United States | $0.077B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.073B | 0.00 |
| Pulmonx (LUNG) | United States | $0.058B | 0.00 |
| 111 (YI) | China | $0.057B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.052B | 0.00 |
| Precipio (PRPO) | United States | $0.049B | 0.00 |
| HeartBeam (BEAT) | United States | $0.047B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.034B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.018B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.017B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.011B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.009B | 0.00 |
| Zhongchao (ZCMD) | China | $0.008B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| ITonic Holdings (ITOC) | China | $0.005B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.002B | 0.00 |
| PROFUSA (PFSA) | United States | $0.001B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |